Chromosomal Instability in Ovarian Cancer
Study Details
Study Description
Brief Summary
Chromosomal instability (CIN) refers to the ongoing genomic change, which involves the amplification or deletion of chromosome copy number or structure. The changes rang from point mutation to small-scale genomic change and even the change of whole chromosome number. It has been reported that the characteristics of genomic rearrangement can be used as a marker of clinical outcome of high-grade serous ovarian cancer, and specific genomic rearrangement are related to the poor prognosis. In noninvasive gene detection with low coverage, patients diagnosed with ovarian cancer have deteriorating progression-free and overall survivals regardless of the tumor stage when somatic copy number distortion (sCNA) exceeds the threshold in plasma. The detection rate of sCNA increased along with the tumor stage. We enrolled those as our target patients, who are diagnosed with high-grade serous ovarian cancer and willing to take part in. The CIN in peripheral cell-free DNA was observed before initial treatment, after primary debulking or staging surgeries, before recurrence and during the process of recurrence treatment. Our aim is to explore the application of CIN in peripheral tumor DNA in the detection of minimal residual lesions (MRD) after primary treatment and recurrence monitoring.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Incidence of chromosomal instability (CIN) [One year]
Incidence of chromosomal instability tested in peripheral cell-free DNA
Secondary Outcome Measures
- Progression-free survival [One year]
Progression-free survival in patients accepting CIN testing
- Overall survival [One year]
Overall survival in patients accepting CIN testing
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Confirmed of primary ovarian high grade serous carcinoma (HGSC)
-
Aged 18 years or older
-
Acceptance of surgical treatment for HGSC
-
With detailed follow-up outcomes
Exclusion Criteria:
-
Not meeting all of the inclusion criteria
-
Declining to anticipate the trial
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Lei Li | Beijing | Beijing | China | 100730 |
Sponsors and Collaborators
- Lei Li
Investigators
- Principal Investigator: Lei Li, M.D., Peking Union Medical College Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- EOC-CIN